Novartis AG (NOVN.SIX) AI OPINIONS & ADVISOR ANALYSIS

The bull case activates if Avidity's neuromuscular assets and remibrutinib convert science into scale simultaneously. Approvals in Duchenne and myotonic dystrophy, plus a remibrutinib MS launch, would restore a credible multi-billion growth stack and let management finally lift medium-term guidance as it has hinted [7]. Confidence returns, the buyback continues against a rising earnings base, and the multiple re-rates toward 17x core. A weaker franc would then amplify the CHF-quoted return further.

The bear case activates when two clocks strike together: a Cosentyx biosimilar arriving before 2030 while the 0% tariff tier lapses in January 2029 [25][28]. Earnings would face simultaneous volume, price and cost shocks with net debt already at USD 39.4bn and long-dated funding priced near 5.7% [8][9]. Buybacks would be curtailed to defend the rating, removing the per-share support, and the multiple would compress toward 11-12x. A firm franc would deepen the CHF loss.

The settled belief is that Novartis is a de-risked defensive compounder that has already absorbed its patent cliff. Consensus treats the launch cohort as sufficient and prices roughly 15x forward core earnings — above Goldman's cautious 13.6x Sell anchor [27] — even after pelacarsen failed. The anchoring bias is on core EPS, which excludes the amortisation of USD 15.3bn of H1 acquisitions.

The crowd modestly overestimates these shares. Follow the evidence: the multiple expanded through a quarter in which IFRS net income fell 19%, the group lost a USD 6bn-peak-sales asset [13], and net debt nearly doubled to USD 39.4bn [8]. The bull case now rests on core EPS, a measure that excludes amortisation of the very acquisitions funding the growth. Add a time-boxed tariff shield expiring January 2029 [25] and the franc translation risk, and the fair multiple looks nearer 13-14x than 15x.

The 18-19 November 2026 investor event in London is the reckoning [3]: management must reset or reaffirm mid-term guidance without pelacarsen. The first observable sign of repricing is whether the growth algorithm is restated using IFRS rather than core metrics, and whether 2029-2030 CAGR language survives intact.